Human leukocyte antigen class I and class II peptide-binding grooves (HLA-I/II peptide-binding grooves)

The Human Leukocyte Antigen (HLA) class I and class II peptide-binding grooves are specialized structural domains on the surface of antigen-presenting cells that play a pivotal role in the adaptive immune system. These grooves, formed by alpha-helices and a beta-sheet floor, function to capture and display short peptide fragments to T-cell receptors, thereby facilitating the recognition of self versus non-self (Janeway et al., 2001). HLA class I grooves typically present 8-10 amino acid peptides to CD8+ T-cells, whereas HLA class II grooves accommodate longer peptides for presentation to CD4+ T-cells (Murphy & Weaver, 2016). These sites are the most polymorphic regions in the human genome, which directly influences individual susceptibility to infectious diseases, cancers, and autoimmune disorders. Pharmacologically, these grooves are critical in drug hypersensitivity syndromes; for example, abacavir binds non-covalently within the HLA-B*57:01 groove, altering the repertoire of presented self-peptides and triggering a T-cell mediated immune response (Illing et al., 2012). Additionally, therapeutic agents like glatiramer acetate target these grooves to competitively inhibit the presentation of myelin-derived autoantigens in multiple sclerosis (Teitelbaum et al., 1999).

Other names

MHC peptide-binding cleftHLA binding pocketMajor histocompatibility complex peptide-binding grooveHLA antigen-binding siteMHC class I and II binding grooves

Pharmacological agents interact with HLA peptide-binding grooves through competitive displacement of endogenous peptides or by occupying specific pockets within the groove to alter the binding specificity (the altered repertoire model), which can either suppress unwanted immune responses or inadvertently trigger T-cell activation against self-antigens.